Articles by Melissa Badamo
While azacitidine plus venetoclax is a feasible treatment option, it did not improve patients outcomes.
The phase 1 ALPHA2/ALPHA studies demonstrate cema-cel's safety and efficacy in relapsed LBCL.
The phase 3 SENTRY trial will randomize patients to ruxolitinib plus placebo or selinexor plus placebo.
This issue includes a feature on trispecifics in myeloma, a Get to Know interview with Dr. Raajit Rampal, and more.
From Buffalo to the Manhattan borough, Dr. Rampal shares his journey to becoming a hematologist-oncologist.
Nuvisertib, an oral, investigational, highly selective PIM1 kinase inhibitor, showed clinical activity in a phase 1/2 study.
Dr. John Mascarenhas discussed novel type 2 JAK inhibitors for myelofibrosis, such as AJ1-11095 and INCB160058.
The name change will take effect on August 28, ahead of Blood Cancer Awareness Month in September.
As director of the FDA’s CBER, Dr. Prasad oversaw the regulation of biological products for human use.
Dr. Vose outlined the biggest takeaways from the CLL session at the 2025 Pan Pacific Leukemia Conference.
Pirtobrutinib demonstrated a superior PFS of 14 months, compared with 8.7 months with investigator’s choice.
The document reflects the FDA’s recommendations for drug development, clinical trial designs, efficacy end points, and ...
The FDA raised concerns about the high rates of ocular toxicity in the DREAMM-7 and DREAMM-8 trials.
Atara Biotherapeutics has transferred the Investigational New Drug Application for tabelecleucel.
Dr. Swoboda discusses his role as clinical investigator of the QuANTUM-Wild study, how AI can transform oncology, and more.
This issue includes a feature on hospital partnerships in oncology, a Get to Know interview with David Swoboda, and more.
The FDA has accepted a Supplemental New Drug Application for decitabine and cedazuridine plus venetoclax for AML.
The study investigated the role of multi-cancer early detection tests (MCEDs) on patient survival outcomes.
Gaps in coordination and collaboration between primary care and oncology may impact long-term survival outcomes for patients.
SGR-1505 has shown promising efficacy and safety in an ongoing, phase 1 dose-escalation study.
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.